MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展

doi:10.3760/cma.j.cn371439-20221213-00037

摘要/Abstract

摘要：

近年来，免疫治疗尤其是免疫检查点抑制剂在延长肿瘤晚期患者生存期方面显现出明显优势，肿瘤微环境是影响免疫疗效的重要因素之一。微卫星稳定型结直肠癌患者在联合免疫检查点抑制剂治疗中表现出免疫应答。深入探索微卫星稳定型结直肠癌的肿瘤微环境特点以及应用免疫检查点抑制剂联合治疗策略，可为结直肠癌免疫治疗提供新的思路和方向。

关键词: 结直肠肿瘤, 肿瘤微环境, 免疫疗法, 微卫星稳定型

Abstract:

In recent years， immunotherapy， especially immune checkpoint inhibitors， has shown obvious advantages in prolonging the survival of patients with advanced tumors， and the tumor microenvironment is one of the important factors affecting the efficacy of immunity. Patients with microsatellite-stable colorectal cancer exhibit immune responses in combination with immune checkpoint inhibitor therapy. In-depth exploration of the tumor microenvironment characteristics of microsatellite-stable colorectal cancer and the application of combined immune checkpoint inhibitor therapy can provide new ideas and directions for colorectal cancer immunotherapy.

Key words: Colorectal neoplasms, Tumor microenvironment, Immunotherapy, Microsatellite stable

徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.

Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.

参考文献 51

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Boukouris AE, Theochari M, Stefanou D, et al. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: a 2022 update[J]. Crit Rev Oncol Hematol, 2022, 173: 103663. DOI: 10.1016/j.critrevonc.2022.103663. doi: 10.1016/j.critrevonc.2022.103663
[3]	Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2022, 23(5): 659-670. DOI: 10.1016/S1470- 2045(22)00197-8.
[4]	Ganesh K. Optimizing immunotherapy for colorectal cancer[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(2): 93-94. DOI: 10.1038/s41575-021-00569-4. doi: 10.1038/s41575-021-00569-4
[5]	Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment[J]. Cancer Discov, 2021, 11(4): 933-959. DOI: 10.1158/2159-8290.CD-20-1808. doi: 10.1158/2159-8290.CD-20-1808 pmid: 33811125
[6]	Chen L, Jiang X, Li Y, et al. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC[J]. Clin Immunol, 2022, 237: 108962. DOI: 10.1016/j.clim.2022.108962. doi: 10.1016/j.clim.2022.108962
[7]	郭龙, 孙永杰. T淋巴细胞亚群、NK细胞与结直肠癌患者病理分期的关系[J]. 航空航天医学杂志, 2022, 33(9): 1064-1067. DOI: 10.3969/j.issn.2095-1434.2022.09.015. doi: 10.3969/j.issn.2095-1434.2022.09.015
[8]	van der Veeken J, Campbell C, Pritykin Y, et al. Genetic tracing reveals transcription factor Foxp3-dependent and Foxp3-independent functionality of peripherally induced Treg cells[J]. Immunity, 2022, 55(7): 1173-1184. e7. DOI: 10.1016/j.immuni.2022.05.010. doi: 10.1016/j.immuni.2022.05.010 pmid: 35700740
[9]	Boissière-Michot F, Lazennec G, Frugier H, et al. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer[J]. Oncoimmunology, 2014, 3(6): e29256. DOI: 10.4161/onci.29256. doi: 10.4161/onci.29256
[10]	Masuda K, Kornberg A, Miller J, et al. Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer[J]. JCI Insight, 2022, 7(7): e154646. DOI: 10.1172/jci.insight.154646. doi: 10.1172/jci.insight.154646
[11]	Wu D, Zhu Y. Role of kynurenine in promoting the generation of exhausted CD8⁺ T cells in colorectal cancer[J]. Am J Transl Res, 2021, 13(3): 1535-1547.
[12]	Zhang X, Liu X, Zhou W, et al. Blockade of IDO-kynurenine-AhR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(4): 1179-1199. DOI: 10.1016/j.jcmgh.2021.05.018. doi: 10.1016/j.jcmgh.2021.05.018 pmid: 34087454
[13]	Hegde S, Leader AM, Merad M. MDSC: markers, development, states, and unaddressed complexity[J]. Immunity, 2021, 54(5): 875-884. DOI: 10.1016/j.immuni.2021.04.004. doi: 10.1016/j.immuni.2021.04.004 pmid: 33979585
[14]	Yin K, Xia X, Rui K, et al. Myeloid-derived suppressor cells: a new and pivotal player in colorectal cancer progression[J]. Front Oncol, 2020, 10: 610104. DOI: 10.3389/fonc.2020.610104. doi: 10.3389/fonc.2020.610104
[15]	李奕建, 钟世彪, 陈利生. 外周血MDSC水平及NLR、PLR比值对结直肠癌患者临床预后评估的价值[J]. 中华细胞与干细胞杂志(电子版), 2019, 9(3): 149-153. DOI: 10.3877/cma.j.issn.2095-1221.2019.03.004. doi: 10.3877/cma.j.issn.2095-1221.2019.03.004
[16]	Bhat AA, Nisar S, Singh M, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy[J]. Cancer Commun (Lond), 2022, 42(8): 689-715. DOI: 10.1002/cac2.12295. doi: 10.1002/cac2.12295
[17]	Li S, Na R, Li X, et al. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(4): 188758. DOI: 10.1016/j.bbcan.2022.188758. doi: 10.1016/j.bbcan.2022.188758
[18]	Liu C, Liu R, Wang B, et al. Blocking IL-17a enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer[J]. J Immunother Cancer, 2021, 9(1): e001895. DOI: 10.1136/jitc-2020-001895. doi: 10.1136/jitc-2020-001895
[19]	Kim CG, Jang M, Kim Y, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers[J]. Sci Immunol, 2019, 4(41): eaay0555. DOI: 10.1126/sciimmunol.aay0555. doi: 10.1126/sciimmunol.aay0555
[20]	Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment[J]. Int J Clin Oncol, 2020, 25(5): 801-809. DOI: 10.1007/s10147-020-01666-1. doi: 10.1007/s10147-020-01666-1 pmid: 32246277
[21]	Seyedin SN, Hasibuzzaman MM, Pham V, et al. Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 81-92. DOI: 10.1016/j.ijrobp.2020.01.030. doi: 10.1016/j.ijrobp.2020.01.030
[22]	Yang J, Zhou W, Ma Y, et al. The response of PD-1 inhibitor combined with radiotherapy and GM-CSF(PRaG) with or without IL-2 in microsatellite stable metastatic colorectal cancer: analysis of pooled data from two phase Ⅱ trials[J]. J Clin Oncol, 2022, 40(suppl 16): e15561. DOI: 10.1200/JCO.2022.40.16_suppl.e15561. doi: 10.1200/JCO.2022.40.16_suppl.e15561
[23]	Yang J, Bi F, Gou H. Complete pathologic response after concurrent treatment with pembrolizumab and radiotherapy in metastatic colorectal cancer: a case report[J]. Onco Targets Ther, 2021, 14: 2555-2561. DOI: 10.2147/OTT.S298333. doi: 10.2147/OTT.S298333
[24]	Guan Y, Kraus SG, Quaney MJ, et al. FOLFOX chemotherapy ameliorates CD8 T lymphocyte exhaustion and enhances checkpoint blockade efficacy in colorectal cancer[J]. Front Oncol, 2020, 10: 586. DOI: 10.3389/fonc.2020.00586. doi: 10.3389/fonc.2020.00586 pmid: 32391270
[25]	Men Q, Huang J, Duan Y, et al. PD-1 blockade combined chemotherapy and bevacizumab in DNA mismatch repair-proficient/microsatellite stable colorectal liver metastases[J]. J Clin Oncol, 2022, 40(suppl 16): e15547. DOI: 10.1200/JCO.2022.40.16_suppl.e15547. doi: 10.1200/JCO.2022.40.16_suppl.e15547
[26]	Zheng Y, Fu Y, Wang PP, et al. Neoantigen: a promising target for the immunotherapy of colorectal cancer[J]. Dis Markers, 2022, 2022: 8270305. DOI: 10.1155/2022/8270305. doi: 10.1155/2022/8270305
[27]	Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker[J]. Cancer Cell, 2021, 39(2): 154-173. DOI: 10.1016/j.ccell.2020.10.001. doi: 10.1016/j.ccell.2020.10.001 pmid: 33125859
[28]	Westcott PMK, Sacks NJ, Schenkel JM, et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer[J]. Nat Cancer, 2021, 2(10): 1071-1085. DOI: 10.1038/s43018-021-00247-z. doi: 10.1038/s43018-021-00247-z
[29]	Caushi JX, Zhang J, Ji Z, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers[J]. Nature, 2021, 596(7870): 126-132. DOI: 10.1038/s41586-021-03752-4. doi: 10.1038/s41586-021-03752-4
[30]	Graham LS, Pritchard CC, Schweizer MT. Hypermutation, mismatch repair deficiency, and defining predictors of response to checkpoint blockade[J]. Clin Cancer Res, 2021, 27(24): 6662-6665. DOI: 10.1158/1078-0432.CCR-21-3031. doi: 10.1158/1078-0432.CCR-21-3031 pmid: 34580112
[31]	Tondini E, Arakelian T, Oosterhuis K, et al. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control[J]. Oncoimmunology, 2019, 8(11): 1652539. DOI: 10.1080/2162402X.2019.1652539. doi: 10.1080/2162402X.2019.1652539
[32]	Palmer CD, Rappaport AR, Davis MJ, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results[J]. Nat Med, 2022, 28(8): 1619-1629. DOI: 10.1038/s41591-022-01937-6. doi: 10.1038/s41591-022-01937-6 pmid: 35970920
[33]	Suarez-Carmona M, Williams A, Schreiber J, et al. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects[J]. J Immunother Cancer, 2021, 9(10): e002505. DOI: 10.1136/jitc-2021-002505. doi: 10.1136/jitc-2021-002505
[34]	Liu N, Shan F, Ma M. Strategic enhancement of immune checkpoint inhibition in refractory colorectal cancer: trends and future prospective[J]. Int Immunopharmacol, 2021, 99: 108017. DOI: 10.1016/j.intimp.2021.108017. doi: 10.1016/j.intimp.2021.108017
[35]	Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivo-lumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phaseⅠb trial (REGONIVO, EPOC1603)[J]. J Clin Oncol, 2020, 38(18): 2053-2061. DOI: 10.1200/JCO.19.03296. doi: 10.1200/JCO.19.03296 pmid: 32343640
[36]	Wang Y, Wei B, Gao J, et al. Combination of fruquintinib and anti-PD-1 for the treatment of colorectal cancer[J]. J Immunol, 2020, 205(10): 2905-2915. DOI: 10.4049/jimmunol.2000463. doi: 10.4049/jimmunol.2000463 pmid: 33028620
[37]	Fang X, Zhong C, Zhu N, et al. A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer[J]. J Clin Oncol, 2022, 40(16_suppl): 3563. DOI: 10.1200/JCO.2022.40.16_suppl.3563. doi: 10.1200/JCO.2022.40.16_suppl.3563
[38]	Huyghe N, De Cuyper A, Sinapi I, et al. Interim analysis of the phase Ⅱ AVETUXIRI trial: avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)[J]. J Clin Oncol, 2022, 40(16_suppl): 3595. DOI: 10.1200/JCO.2022.40.16_suppl.3595. doi: 10.1200/JCO.2022.40.16_suppl.3595
[39]	Bocobo AG, Wang R, Behr S, et al. Phase Ⅱ study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)[J]. J Clin Oncol, 2022, 40(16_suppl): 3565. DOI: 10.1200/JCO.2022.40.16_suppl.3565. doi: 10.1200/JCO.2022.40.16_suppl.3565
[40]	Malogolovkin A, Gasanov N, Egorov A, et al. Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes[J]. Viruses, 2021, 13(7): 1271. DOI: 10.3390/v13071271. doi: 10.3390/v13071271
[41]	Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy[J]. Curr Opin Biotechnol, 2020, 65: 25-36. DOI: 10.1016/j.copbio.2019.11.016. doi: 10.1016/j.copbio.2019.11.016
[42]	Ma R, Li Z, Chiocca EA, et al. The emerging field of oncolytic virus-based cancer immunotherapy[J]. Trends Cancer, 2023, 9(2): 122-139. DOI: 10.1016/j.trecan.2022.10.003. doi: 10.1016/j.trecan.2022.10.003
[43]	Carr MJ, Sun J, DePalo D, et al. Talimogene laherparepvec (T-VEC) for the treatment of advanced locoregional melanoma after failure of immunotherapy: an international multi-institutional experience[J]. Ann Surg Oncol, 2022, 29(2): 791-801. DOI: 10.1245/s10434-021-10910-5. doi: 10.1245/s10434-021-10910-5
[44]	Ahamadi M, Kast J, Chen PW, et al. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma[J]. CPT Pharmacometrics Syst Pharmacol, 2023, 12(2): 250-260. DOI: 10.1002/psp4.12898. doi: 10.1002/psp4.12898
[45]	Kim C, Chon HJ, Lee HJ, et al. Abstract 1914: orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer[J]. Cancer Res, 2021, 81(13_Supplement): 1914. DOI: 10.1158/1538-7445. AM2021-1914. doi: 10.1158/1538-7445.AM2021-2021
[46]	Zhang B, Huang J, Tang J, et al. Intratumoral OH₂, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase Ⅰ/Ⅱ clinical trial[J]. J Immunother Cancer, 2021, 9(4): e002224. DOI: 10.1136/jitc-2020-002224. doi: 10.1136/jitc-2020-002224
[47]	Morelli MP, Xie C, Brar G, et al. A phase Ⅰ/Ⅱ study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: safety report[J]. J Clin Oncol, 2019, 37(suppl 4): 646. DOI: 10.1200/JCO.2019.37.4_suppl.646. doi: 10.1200/JCO.2019.37.4_suppl.646
[48]	Coupez D, Hulo P, Touchefeu Y, et al. Pembrolizumab for the treatment of colorectal cancer[J]. Expert Opin Biol Ther, 2020, 20(3): 219-226. DOI: 10.1080/14712598.2020.1718095. doi: 10.1080/14712598.2020.1718095 pmid: 31952453
[49]	Verschoor YL, van den Berg J, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study[J]. J Clin Oncol, 2022, 40(16_suppl): 3511. DOI: 10.1200/JCO.2022.40.16_suppl.3511. doi: 10.1200/JCO.2022.40.16_suppl.3511
[50]	Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study[J]. JAMA Oncol, 2020, 6(6): 831-838. DOI: 10.1001/jamaoncol.2020.0910. doi: 10.1001/jamaoncol.2020.0910 pmid: 32379280
[51]	Chen Y, Liu C, Zhu S, et al. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: immunotherapeutic amplification strategies against colorectal cancer[J]. Int Immunopharmacol, 2021, 96: 107607. DOI: 10.1016/j.intimp.2021.107607. doi: 10.1016/j.intimp.2021.107607